Preferences For Treatment Attributes Of Dulaglutide And Liraglutide Among Patients With Type 2 Diabetes Mellitus And Their Willingness To Self-Inject Diabetes Medication: A Comparison Between Japan And The United Kingdom

Abstract

attributes: dosing frequency, blood sugar (HbA1c) change, weight change, type of delivery system, frequency of nausea, and frequency of hypoglycemia. Part-worth utilities were estimated using logit regression models and used to calculate relative importance (RI) values for each attribute. Prior to completion of the DCE, participants were queried about willingness to self-inject medication for T2DM. Following the DCE, participants were asked their willingness to take medication represented by dulaglutide and liraglutide medication profiles. Results: Final analytic samples consisted of 182 participants in Japan and 243 from the UK. In both studies, dosing frequency, type of delivery system, and frequency of nausea were the top 3 most important attributes, in rank order, with minor variation in the relative importance of each attribute across countries. Pre-study willingness to take injectable medication was significantly lower in Japan (1.7%) compared to the UK (37.9%) (p< 0.0001). Post-DCE willingness to take medication represented by dulaglutide and liraglutide medication profiles also differed, with fewer Japanese participants 'somewhat willing' or 'very willing' (dulaglutide: 42.9%; liraglutide: 4.4%) compared to their UK counterparts (dulaglutide: 77.0%; liraglutide: 30.5%). ConClusions: Rank-order of RI for treatment characteristics of dulaglutide and liraglutide were similar across countries with dosing frequency ranked highest, followed by type of delivery system. Patients from both countries were more willing to self-inject at the end of the study; UK patients were more willing than Japanese patients at both time points.